Oisìn Biotechnologies Raises $5M in Seed Funding
- Oisìn Biotechnologies, a Seattle WA-based company that specializes in mitigating the effects of age-related diseases, raised $5M in seed funding
- The round, which brought total funding to $9.5m, was led by Althea Group, LLC
- The company intends to use the funds for the preclinical development of its platform and investigational therapy for kidney and other age-related diseases
- Oisín is a late preclinical stage company developing therapeutics to reduce the effects of the aging process
- The company’s first therapies target senescent cells using its proprietary technology platform, SENSOlytics
- Its DNA-based interventions are designed to clear senescent cells, which can trigger aging pathologies and shorten lifespan, from the body
